Top insider buys and sells disclosed on Friday

On Friday, insiders made notable trades in US-listed companies. Baker Bros. bought $35M in Madrigal Pharmaceuticals (MDGL) shares, Kinder Morgan's (KMI) CEO bought $15M in stock, and Kennametal's (KMT) CEO acquired $165k in shares. Meanwhile, Royal Caribbean's (RCL) director sold $82M in stock, and Gilead's (GILD) CEO sold $19.7M in shares. InvestingPro analysis suggests some stocks are undervalued or overvalued.

Original reporting
Published Nov 9, 2026, 2:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 9, 2026, 2:12 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$MDGL
Bullish
medium confidence
Mentioned
$MDGL · $KMI · $KYN · $KMT · $TTMI · $RCL
Relevance
4/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$MDGLBullishLow
01

Why it matters

While insider trades provide clues, the overall market impact is likely muted given the routine nature of most transactions.

02

Market read

Insider activity may influence short‑term price moves for the listed tickers but does not constitute a market‑wide catalyst.

03

What to watch

Many purchases are at low price levels; market may already price in insider confidence.

Relevance 4/10Novelty 3/10Timing: today

Background

The article aggregates recent Form 4 filings for US‑listed companies, highlighting notable insider purchases and sales.

Company-level read

Ticker impact

$MDGLBullishMedium confidence
Context

Director Julian C. Baker and affiliates bought 91,806 shares for $35.0M, signaling confidence amid a 31% YTD decline.

Expected impact

likely modest upside as market prices in insider confidence

Evidence & confidence

Large purchase at near 52‑week low suggests belief the stock is undervalued.

$KMIBullishMedium confidence
Context

Executive Chairman Richard D. Kinder purchased 500,000 shares for $15.0M, adding to his holdings.

Expected impact

likely slight upward bias as a major insider adds a sizable block

Evidence & confidence

Buy by a 10% owner signals confidence despite recent 11% weekly dip.

$KYNBullishLow confidence
Context

President James C. Baker bought 25,000 shares for $331,085.

Expected impact

potential modest lift

Evidence & confidence

Small purchase relative to market cap; limited impact.

$KMTBullishLow confidence
Context

CEO Sanjay Chowbey acquired 7,000 shares for $165,368.

Expected impact

possible slight upside

Evidence & confidence

Insider buy at near 52‑week low, but size is modest.

$TTMIBullishLow confidence
Context

Director Wajid Ali bought 10,000 shares for $631,541.

Expected impact

likely minimal upward pressure

Evidence & confidence

Purchase size modest relative to recent 25% weekly decline.

$RCLBearishMedium confidence
Context

Director Arne Alexander Wilhelmsen sold 240,000 shares for $82.1M.

Expected impact

likely slight sell pressure

Evidence & confidence

Large insider sale may signal concerns despite recent price gains.

$SNBearishMedium confidence
Context

CEO Mark Barrocas sold 113,156 shares for $25.0M.

Expected impact

potential modest downside

Evidence & confidence

Significant insider sell near 52‑week high could be viewed as profit taking.

$GILDBearishMedium confidence
Context

CEO Daniel O’Day sold ~112,429 shares for $19.7M under a 10b5‑1 plan, while also exercising options worth $8.1M.

Expected impact

likely slight downward bias

Evidence & confidence

Large net sale near 52‑week high suggests reduced confidence.

Market effects

Insider activity across healthcare, energy, industrials may hint at sector confidence trends.

US market sentiment may be modestly influenced by high‑profile insider buys in energy and biotech.

Limited; primarily US‑focused insider transactions.

Counterpoint

Large insider sells could signal underlying concerns despite recent price gains.

Key entities

  • Julian C. Baker

    Director of Madrigal Pharmaceuticals, insider buyer.

  • Richard D. Kinder

    Kinder Morgan insider buyer.

  • Arne Alexander Wilhelmsen

    Royal Caribbean insider seller.

Related articles

Med

Kennametal India FY26 Results: PBT up 90% to ₹2,663 mn

Kennametal India reported a 90% YoY increase in PBT to ₹2,663 mn and 29% revenue growth to ₹15,107 mn for FY26. Aerospace & Defense segment grew 67%, while Hard Metal division revenue rose 31.8%. Q2 net profit increased to ₹107 crore from ₹31.4 crore YoY, with revenue at ₹552 crore and EBITDA margin expanding to 28.09%.

$GSKMed

The Liver Meeting 2026 Highlights Hepatitis Delta, PBC Targets, MASH Costs

The Liver Meeting 2026 highlighted advancements in hepatitis delta, PBC, and MASH treatments. Vir Biotechnology's elebsiran and Mirum Pharmaceuticals' brelovitug showed promising phase 3 results for hepatitis delta, with regulatory submissions expected in 2027. GSK's bepirovirsen received FDA approval for hepatitis B. Merck's efinopegdutide and Altimmune's pemvidutide showed potential in MASH treatment. Real-world data indicated cost concerns with MASH therapies.

$RCLMed

Morgan Stanley raises Royal Caribbean stock price target on cost control

Morgan Stanley raised its price target for Royal Caribbean (RCL) to $330 from $300, citing improved cost control and lower fuel costs. The stock is up 31% over six months. Morgan Stanley also increased earnings forecasts by 2-3% but cut its 2027 yield growth forecast. RCL reported strong Q3 results with $6.57 EPS and $5.59B revenue. Other analysts have raised price targets and ratings.

$KMILow

Safety Concerns Over Tennessee Kinder Morgan Pipeline

Kinder Morgan plans a $7.6B 470-mile methane gas pipeline through Tennessee, with 2.6B cubic feet daily capacity. The project, set for 2030, may create 7,000 jobs. The company highlights safety measures like 24/7 monitoring and corrosion protection. Landowner notices are ongoing.